ArticleHealth and quality of life outcomes2026
Latent transitions in quality of life and the influencing factors among patients with first-ever ischemic stroke: a prospective longitudinal study.
Article in Health and quality of life outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundIschemic stroke (IS) is the second leading cause of death and disability globally, with quality of life (QoL) post-stroke influenced by various factors. Conventional static analytical approaches fail to capture the dynamic transitions between health states over time. This study aimed to characterize the temporal evolution of distinct QoL phenotypes and elucidate the phase-specific mechanisms driving these transitions.
methodsIn this prospective longitudinal study, 442 patients with first-ever IS were assessed for QoL using the Stroke-Specific Quality of Life Scale (SS-QoL) at the acute phase (T0), 1 month (T1), 3 months (T2), and 6 months (T3). Latent Profile Analysis (LPA) was utilized to identify distinct QoL phenotypes, while Latent Transition Analysis (LTA) modeled the probabilities of shifting between latent states. Multi-period Firth’s penalized logistic regression was employed to identify stage-specific determinants of improvement or deterioration across recovery intervals.
resultsThree distinct QoL classes (high, moderate, and low) were identified at four time points. The high QoL class exhibited stability but was vulnerable to late declines, while the moderate QoL class showed frequent fluctuations. The low QoL class showed potential for improvement but was at risk for persistent poor outcomes. During the T0-T1 period, improvement was significantly impeded by metabolic and physiological burdens—specifically elevated LDL (β = -0.495, p = 0.013), venous thromboembolism risk (β = -0.990, p = 0.008), and higher Body Roundness Index (β = -0.424, p = 0.001)—but facilitated by left-sided hemiparesis (β = 0.746, p = 0.032). For the transition in the T1-T2 phase, higher LDL levels (β = 0.793, p = 0.047) significantly increased the odds of deterioration, whereas higher total cholesterol (β = -0.620, p = 0.022) reduced it. During the T2-T3 period, resilience (β = -0.054, p = 0.012) and greater functional exercise adherence at 6 months (β = -0.035, p = 0.007) were linked to reduced deterioration.
conclusionsTransitions between post-stroke QoL states are driven by divergent determinants across recovery phases. The management of IS should follow a continuous, phased approach that prioritizes early control of vascular and metabolic risk factors, sustained engagement in functional rehabilitation over the long term, and systematic integration of psychological support in the later stages, in order to optimize long-term QoL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.